<div id="readability-page-1"><p>Cingulate (NASDAQ:CING - Get Free Report) is expected to issue its  Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.</p><p>Cingulate (NASDAQ:CING - Get Free Report) last announced its quarterly earnings results on Wednesday, March 18th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.28).  On average, analysts expect Cingulate to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year. </p><h2>Cingulate Stock Up 7.0%</h2><p>Shares of NASDAQ:CING opened at $5.33 on Thursday. Cingulate has a 1 year low of $3.20 and a 1 year high of $11.89. The company has a market cap of $65.30 million, a PE ratio of -1.23 and a beta of -0.81. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.16 and a quick ratio of 1.16. The stock's 50-day moving average is $6.46 and its 200 day moving average is $5.24. </p><h2>Analyst Upgrades and Downgrades</h2><p>CING has been the topic of a number of research analyst reports. Roth Mkm reduced their price target on Cingulate from $16.00 to $14.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, March 23rd. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of Cingulate in a report on Monday, April 20th. Finally, Ascendiant Capital Markets reduced their price target on Cingulate from $58.00 to $55.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating and one  has assigned  a Sell rating to the company's stock. According to data from MarketBeat.com, Cingulate currently has a consensus rating of &#34;Hold&#34; and an average price target of $34.50.</p><p><b>Get Our Latest Research Report on CING</b></p><h2>Insider Buying and Selling</h2><p>In other news, Director Peter J. Werth bought 19,455 shares of Cingulate stock in a transaction on Friday, February 6th. The shares were purchased at an average price of $5.04 per share, for a total transaction of $98,053.20. Following the acquisition, the director owned 117,449 shares of the company's stock, valued at approximately $591,942.96. The trade was a 19.85% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Shane J. Schaffer bought 6,809 shares of Cingulate stock in a transaction on Friday, February 6th. The shares were purchased at an average price of $5.04 per share, for a total transaction of $34,317.36. Following the acquisition, the chief executive officer directly owned 10,175 shares in the company, valued at approximately $51,282. This trade represents a 202.29% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 33,074 shares of company stock worth $166,693 in the last quarter. Company insiders own  4.33% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC grew its holdings in shares of  Cingulate by 29.8% during the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company's stock worth $529,000 after acquiring an additional 27,979 shares during the period.  Geode Capital Management LLC grew its holdings in shares of  Cingulate by 43.9% during the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company's stock worth $265,000 after acquiring an additional 18,629 shares during the period.  DRW Securities LLC purchased a new position in shares of  Cingulate during the 4th quarter worth approximately $255,000.  XTX Topco Ltd purchased a new position in shares of  Cingulate during the 4th quarter worth approximately $90,000.  Finally, Quadrature Capital Ltd purchased a new stake in shares of  Cingulate in the 4th quarter worth approximately $66,000. Hedge funds and other institutional investors own  41.31% of the company's stock. </p><h2>Cingulate Company Profile</h2> (Get Free Report)<p>Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Cingulate</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0lORw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0lORw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cingulate Right Now?</h2><p>Before you consider Cingulate, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cingulate wasn't on the list.</p><p>While Cingulate currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CING

LABU

<p>Cingulate (NASDAQ:CING) is set to release its Q1 2026 earnings on May 14, with analysts expecting a loss of $0.53 per share. The company previously reported a loss of $0.84 per share for Q1 2025, missing estimates. Cingulate's stock has risen 7% recently, trading at $5.33, with a market cap of $65.30 million. Insider buying has increased, with significant purchases by Director Peter J. Werth and CEO Shane J. Schaffer. Institutional investors hold 41.31% of the stock, and the company focuses on ADHD and anxiety treatments.</p>

Cingulate (CING) to Release Quarterly Earnings on Thursday